IVA logo

Inventiva SA (IVA) Company Overview

Profile

Full Name:

Inventiva S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

July 10, 2020

Indexes:

Not included

Description:

Inventiva SA is a biopharmaceutical company focused on developing innovative treatments for diseases with high unmet medical needs. They specialize in research and development of new drugs, particularly for metabolic and fibrotic diseases, aiming to improve patients' lives through advanced therapies.

Key Details

Price

$2.53

Annual Revenue

$18.92 M(+47.31% YoY)

Annual EPS

-$2.63(-90.42% YoY)

Annual ROE

-1789.46%

Beta

0.74

Events Calendar

Earnings

Next earnings date:

Mar 26, 2025

Recent quarterly earnings:

Sep 25, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 30, 25 HC Wainwright & Co.
Buy
Nov 22, 24 Stifel
Buy
Nov 12, 24 UBS
Neutral
Oct 15, 24 HC Wainwright & Co.
Buy
Sep 26, 24 Stifel
Buy
Sep 26, 24 HC Wainwright & Co.
Buy
Apr 8, 24 Canaccord Genuity
Buy
Apr 1, 24 HC Wainwright & Co.
Buy
Mar 20, 24 HC Wainwright & Co.
Buy
Mar 8, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
IVA
globenewswire.comJanuary 24, 2025

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
IVA
globenewswire.comDecember 16, 2024

Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that, following the general meeting of the shareholders held on December 11, 2024 (the “General Meeting”), the Board of Directors decided to use the delegations granted by the General Meeting to issue the second phase of Tranche 1 (the “T1 bis Transaction”) for a gross amount of €21.4 million (net amount of €20.1 million) of the multi-tranche equity financing of up to €348 million announced on October 14, 2024 (the “Multi-Tranche Financing”).

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
IVA
globenewswire.comNovember 15, 2024

Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in San Diego California.

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
IVA
globenewswire.comOctober 21, 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type-2-Diabetes (“T2D”) has been accepted as late breaker by the scientific committee of the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 being held November 15 to 19, 2024 in San Diego, California.

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
IVA
globenewswire.comOctober 14, 2024

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24-432, on October 14, 2024, in connection with its financing through the issuance of ordinary shares and pre-funded share warrants

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
IVA
globenewswire.comOctober 14, 2024

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period ended June 30, 2024 of its Half-Year Report (the “2024 Half-Year Report”) with the French financial markets authority, “Autorité des Marchés Financiers” (“AMF”).

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
IVA
globenewswire.comOctober 14, 2024

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced financing of immediately €94.1 million and up to €348 million (the “Transaction”), subject to satisfaction of specified conditions, to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.

Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IVA
zacks.comOctober 1, 2024

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
IVA
globenewswire.comSeptember 25, 2024

Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided a corporate and a financial update for the six months ended June 30, 2024.

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
IVA
globenewswire.comJuly 19, 2024

Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Inventiva SA?
  • Does Inventiva SA pay dividends?
  • What sector is Inventiva SA in?
  • What industry is Inventiva SA in?
  • What country is Inventiva SA based in?
  • When did Inventiva SA go public?
  • Is Inventiva SA in the S&P 500?
  • Is Inventiva SA in the NASDAQ 100?
  • Is Inventiva SA in the Dow Jones?
  • When was Inventiva SA's last earnings report?
  • When does Inventiva SA report earnings?

What is the ticker symbol for Inventiva SA?

The ticker symbol for Inventiva SA is NASDAQ:IVA

Does Inventiva SA pay dividends?

No, Inventiva SA does not pay dividends

What sector is Inventiva SA in?

Inventiva SA is in the Healthcare sector

What industry is Inventiva SA in?

Inventiva SA is in the Biotechnology industry

What country is Inventiva SA based in?

Inventiva SA is headquartered in France

When did Inventiva SA go public?

Inventiva SA's initial public offering (IPO) was on July 10, 2020

Is Inventiva SA in the S&P 500?

No, Inventiva SA is not included in the S&P 500 index

Is Inventiva SA in the NASDAQ 100?

No, Inventiva SA is not included in the NASDAQ 100 index

Is Inventiva SA in the Dow Jones?

No, Inventiva SA is not included in the Dow Jones index

When was Inventiva SA's last earnings report?

Inventiva SA's most recent earnings report was on Sep 25, 2024

When does Inventiva SA report earnings?

The next expected earnings date for Inventiva SA is Mar 26, 2025